Company Overview and News
58 of 122 Monthly Paying (MoPay) Canadian (CAD) equities were "safer" by showing positive annual returns, and free cash flow yield greater than dividend yield.
CRIUF BPZZF CHP.UN RNW THO PPRQF CJR.B DREUF MR.UN EFRTF SBC DR.DB.A TRSWF TAHO ARESF SRRTF DR KWH.UN BTBIF PZRIF MFCSF DIR.UN CJREF SRT.UN PZA
52 of 132 monthly paying Canadian "safer" equities showed positive annual returns and free cash flow yield greater than dividend yield per market data gathered 8/27/18.
TAHO KWH.UN BTBIF CRIUF DVSPF CJREF THO CJR.B MR.UN EFRTF SBC
TORONTO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- (TSX: DGS, DGS.PR.A, SBC, SBC.PR.A) Brompton Funds Limited (the “Manager”) is pleased to announce that at special meetings of preferred and class A shareholders (“Shareholders”) of Dividend Growth Split Corp. (“DGS”) and Brompton Split Banc Corp. (“SBC”) held today, Shareholders approved special resolutions to implement amendments to update and modernize the investment objectives, investment strategies and investment restrictions of DGS and SBC as well as certain other matters set out in the joint management information circular dated July 27, 2018 (the “Circular”).
TORONTO, July 16, 2018 (GLOBE NEWSWIRE) -- (TSX:DGS) (TSX:DGS.PR.A) (TSX:SBC) (TSX:SBC.PR.A) Brompton Funds Limited (“Brompton” or the “Manager”), announces special meetings (the “Meetings” and each, a “Meeting”) of holders of Class A Shares and Preferred Shares (the “Shareholders”) of Dividend Growth Split Corp. (“DGS”) and Brompton Split Banc Corp (“SBC”). The purpose of the Meetings is to consider and vote upon extraordinary resolutions to implement amendments to update and modernize the investment objectives, investment strategies and investment restrictions of DGS and SBC (the “Amendments”).
TNTTF DGS TXCX SBC TD TD
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...